Research Report on Pre-HCT Emapalumab Therapy Improving Donor Chimerism in Children with HLH Background and Objective of the Study Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening immune disorder caused by pathological immune activation. The primary mechanism involves the functional deficiency of cytotoxic activity in natural killer (...
Review of the Impact of FISH-Detected Cytogenetic Abnormalities on Prognosis in AL Amyloidosis in the Era of Daratumumab Therapy Background Immunoglobulin light chain (AL) amyloidosis is a rare disease characterized by organ dysfunction caused by the deposition of light chain proteins secreted by abnormal plasma cells. However, the heterogeneous cl...
Utilizing Complement Biosensors to Explore Novel Mechanisms in Complement-Mediated Thrombotic Microangiopathy Background and Necessity Complement-mediated thrombotic microangiopathy (CM-TMA) is a thrombotic microangiopathy caused by complement system dysregulation, with complex clinical manifestations including subtypes such as atypical hemolytic u...
Progress in Molecular Classification of Follicular Lymphoma: A Dual Typing Predictive Model Based on RNA Sequencing and Immunohistochemistry Follicular Lymphoma (FL) is a B-cell malignancy characterized by a slow clinical progression, with a median overall survival extending up to 20 years. However, the heterogeneous nature of FL leads to significa...
Research on Juvenile Xanthogranuloma Reveals Novel Genetic Mutations Juvenile xanthogranuloma (JXG), a rare histiocytic neoplasm, typically manifests in the skin but occasionally presents extracutaneously in locations such as soft tissue or the central nervous system (CNS). The genetic drivers underlying these extracutaneous variants remain poorly ...
Latest Research Report: Idecabtagene Vicleucel (ide-cel) Significantly Extends Progression-Free Survival in Triple-Class Exposed (TCE) Relapsed or Refractory Multiple Myeloma – Results from the KARMMA-3 Clinical Trial Academic Background and Research Question Patients with Multiple Myeloma (MM) often relapse after multiple lines of therapy, with pr...
Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...
Stage-specific Chromosomal Deletions Activate the IRX3 Oncogene in T-cell Acute Lymphoblastic Leukemia In the field of cancer research, understanding regulatory mechanisms of the noncoding genome remains a key focus, especially concerning how oncogenes can be aberrantly activated through non-canonical regulatory pathways. This paper, authored by Su...
Report on the Academic Paper on the Monoclonal Antibody INCA033989 for Targeting Mutated Calreticulin in Myeloid Tumors Background: Calreticulin Mutation-Driven Myeloproliferative Neoplasms Myeloproliferative neoplasms (MPNs) are hematological malignancies caused by somatic mutations occurring in multipotent hematopoietic stem cells (HSCs). These m...
Revisited Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis (FHL) Based on HLH-2004: Updates to Diagnostic Criteria and Development of Multipathway Diagnostic Strategies Introduction Familial hemophagocytic lymphohistiocytosis (FHL) is a severe hyperinflammatory disease characterized by abnormal accumulation of macrophages and l...